SRD5A2 and major depressive disorder: We compared SRD5A1 and/or SRD5A2 promoter methylation in DNA samples obtained from blood and/or CSF in PFS patients and controls and correlated the resulting epigenetic pattern with the neuroactive steroid levels previously found by us to be associated with major depression and sexual side effects (18).